Idera Pharmaceuticals Inc (NASDAQ:IDRA)

Data as of Sep 22
 -0.06 / -2.44%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which is engaged in the discovery and development of novel synthetic DNA- and RNA-based drug candidates that are designed to modulate immune responses mediated through Toll-like Receptors. The company has two drug candidates, IMO-3100, a TLR7 and TLR9 antagonist, and IMO-8400, a TLR7, TLR8, and TLR9 antagonist, in clinical development for the treatment of autoimmune and inflammatory diseases. Idera Pharmaceuticals was founded by Paul C. Zamecnik, Sudhir A. Agrawal and James B. Wyngaarden in May 25, 1989 and is headquartered in Cambridge, MA.

Contact Information

Idera Pharmaceuticals, Inc.
167 Sidney Street
Cambridge Massachusetts 02139
P:(617) 679-5500
Investor Relations:
(617) 679-5517



Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Sudhir A. AgrawalPresident, Chief Executive Officer & Director
Louis J. ArcudiCFO, Secretary, Treasurer & SVP-Operations
Robert D. ArbeitVice President-Clinical Development
Louis BrennerChief Medical Officer & Senior Vice President
Timothy M. SullivanVP-Development Programs & Alliance Management

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.